Designing Phage Therapeutics
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Phage therapy is the application of phages to bodies, substances, or environments to effect the biocontrol of pathogenic or nuisance bacteria. To be effective, phages, minimally, must be capable of attaching to bacteria (adsorption), killing those bacteria (usually associated with phage infection), and otherwise surviving (resisting decay) until they achieve attachment and subsequent killing. While a strength of phage therapy is that phages that possess appropriate properties can be chosen from a large diversity of naturally occurring phages, a more rational approach to phage therapy also can include post-isolation manipulation of phages genetically, phenotypically, or in terms of combining different products into a single formulation. Genetic manipulation, especially in these modern times, can involve genetic engineering, though a more traditional approach involves the selection of spontaneously occurring phage mutants during serial transfer protocols. While genetic modification typically is done to give rise to phenotypic changes in phages, phage phenotype alone can also be modified in vitro, prior to phage application for therapeutic purposes, as for the sake of improving phage lethality (such as by linking phage virions to antibacterial chemicals such as chloramphenicol) or survival capabilities (e.g., via virion PEGylation). Finally, phages, both naturally occurring isolates or otherwise modified constructs, can be combined into cocktails which provide collectively enhanced capabilities such as expanded overall host range. Generally these strategies represent different routes towards improving phage therapy formulations and thereby efficacy through informed design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dispersing biofilms with engineered enzymatic bacteriophage
Lu, T. K., & Collins, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704624104 · Cited by 895
Cited by
Pros and cons of phage therapy
Loc-Carrillo, C., & Abedon, S. T. (2011) · Bacteriophage · doi:10.4161/bact.1.2.14590 · Cited by 1,020
Phage treatment of human infections
Abedon, S. T., Kuhl, S. J., Blasdel, B. G., & Kutter, E. M. (2011) · Bacteriophage · doi:10.4161/bact.1.2.15845 · Cited by 980
Phage Cocktails and the Future of Phage Therapy
Chan, B. K., Abedon, S. T., & Loc-Carrillo, C. (2013) · Future Microbiology · doi:10.2217/fmb.13.47 · Cited by 914
Bacteriophage Host Range and Bacterial Resistance
Hyman, P., & Abedon, S. T. (2010) · Advances in Applied Microbiology · doi:10.1016/s0065-2164(10)70007-1 · Cited by 819
Phage Therapy in Clinical Practice: Treatment of Human Infections
Kutter, E., De Vos, D., Gvasalia, G., Alavidze, Z., Gogokhia, L., Kuhl, S., & Abedon, S. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725401 · Cited by 670
Wittebole, X., De Roock, S., & Opal, S. M. (2014) · Virulence · doi:10.4161/viru.25991 · Cited by 599
Bacteriophages as potential new therapeutics to replace or supplement antibiotics
Kutateladze, M., & Adamia, R. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2010.08.001 · Cited by 483
Phage Choice, Isolation, and Preparation for Phage Therapy
Gill, J., & Hyman, P. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725311 · Cited by 441
Harper, D., Parracho, H., Walker, J., Sharp, R., Hughes, G., Werthén, M., Lehman, S., & Morales, S. (2014) · Antibiotics · doi:10.3390/antibiotics3030270 · Cited by 342
Revisiting phage therapy: new applications for old resources
Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2015) · Trends in Microbiology · doi:10.1016/j.tim.2015.01.006 · Cited by 310
Abedon, S., & Thomas-Abedon, C. (2010) · Current Pharmaceutical Biotechnology · doi:10.2174/138920110790725410 · Cited by 284
Forti, F., Roach, D. R., Cafora, M., Pasini, M. E., Horner, D. S., Fiscarelli, E. V., Rossitto, M., Cariani, L., Briani, F., Debarbieux, L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02573-17 · Cited by 269
Drulis-Kawa, Z., Majkowska-Skrobek, G., Maciejewska, B., Delattre, A.-S., & Lavigne, R. (2012) · Current Protein & Peptide Science · doi:10.2174/138920312804871193 · Cited by 261
Maciejewska, B., Olszak, T., & Drulis-Kawa, Z. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-8811-1 · Cited by 222
Chan, B. K., & Abedon, S. T. (2012) · Advances in Applied Microbiology · doi:10.1016/b978-0-12-394805-2.00001-4 · Cited by 212
Filippov, A. A., Sergueev, K. V., He, Y., Huang, X.-Z., Gnade, B. T., Mueller, A. J., Fernandez-Prada, C. M., & Nikolich, M. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025486 · Cited by 191
“Based on the principle of formulating optimal therapeutic cocktails from the phages that employ different cell surface receptors [29,30,48] and on our results, we recommend six bacteriophages as the best candidates for a plague therapeutic cocktail: QA1122, Pokrovskaya, Y, T7Yp, QJA1, and R.”
BackgroundInfluentialInteraction of phages, bacteria, and the human immune system: Evolutionary changes in phage therapy
Jariah, R. O. A., & Hakim, M. S. (2019) · Reviews in Medical Virology · doi:10.1002/rmv.2055 · Cited by 40
“Proper phage characterisation needs to be fulfilled when designing phage therapy, such as large burst sizes, short latent periods, broad host ranges, and low tendency to provoke resistance.(158) A similar concern is applied in designing a phage cocktail, in which two or more phages are used with purpose to increase th…”
BackgroundBacteriophages as Targeted Therapeutic Vehicles: Challenges and Opportunities
Venkataraman, S., Shahgolzari, M., Yavari, A., & Hefferon, K. (2025) · Bioengineering · doi:10.3390/bioengineering12050469 · Cited by 38
The applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Metadata
- Authors
- Goodridge, L.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 15-27
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2061656601
- Cited by
- 147
- References
- 1
- FWCI
- 7.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.